Refactor
VC Fund
Burlingame, United States
Refactor is a seed stage venture capital firm focused on hard tech investments, in areas such as bio, energy, earth systems, aerospace, manufacturing, and critical materials. It's led by solo capitalist and single employee Zal Bilimoria and is based in Burlingame, California. Refactor now has 5 funds under management since its inception over 10 years ago.
- Total investments:
- 120
- Last investment:
- Lead investor:
- 18%
- Fund size:
- $50M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Refactor invests in
Stages Refactor invests in
Countries Refactor invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2.7M–$11M
- Series A
- $8M–$34M
- Series B
- $16M–$103M
Investment Focus
Industry
- Health Care 32 (27%)
- Biotechnology 29 (24%)
- Medical 12 (10%)
- Artificial Intelligence 10 (8%)
- Life Science 9 (8%)
Stage
- Seed 57 (48%)
- Series A 24 (20%)
- Series B 7 (6%)
- Pre-Seed 4 (3%)
- Series C 4 (3%)
Country
- United States 69 (57%)
- United Kingdom 2 (2%)
- New Zealand 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Zal Bilimoria
Founding Partner
|
Founding Partner | Total investments: 31 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Onyx Bio is a platform that fosters collaboration and community funding for creative projects. By bringing together individuals and groups with shared interests, Cosigned enables them to pool resources and support creative endeavors that might not otherwise be possible. Through its online platform, Onyx Bio streamlines the process of projectmanagement, providing tools for project creators to organize and communicate with their teams, as well as with funders and collaborators. Cosigned is committed to fostering a sense of community and belonging through creativity and collaboration and is dedicated to making the process of creative project development more accessible and equitable for all. | $8M / Seed / Oct 08, 2026 | ||
Pilgrim
|
Pioneering a biologically enhanced future for humanity. | $25M / Seed / Sep 23, 2026 | |
| Biological Black Box integrates biological neurons with artificial neural networks to develop a living computer. | $25M / Seed / Feb 12, 2026 | ||
| Berkeley Yeast engineers yeast strains to help brewers create beers that are delicious and sustainable. The company was founded by Berkeley PhDs in 2017. Its headquarters is based in Oakland, California. They consume around the world, from regional specialties to staples used by billions of people daily. This includes beer and wine, but also bread,cheese, vinegar, soy sauce, fish sauce, kombucha, miso, chocolate, and others. The list is long and reveals a broad and exciting horizon. | Series A / Dec 23, 2025 | ||
| Pila Energy develops innovative battery systems and software to provide energy security and energy management for homes and businesses. The company offers a plug-and-play battery solution for renters and homeowners alike that installs via standard outlets, providing backup power, energy savings, and intelligent load management without complexinstallation overhead. Pila’s system integrates advanced battery storage, power electronics, and mesh networking software to optimize energy use and enhance resilience. Pila Energy was founded in 2024 and is headquartered in San Francisco, CA. | $4M / Seed / Oct 21, 2025 | ||
| Nome is the Operating System for Personalized Therapies™. Where traditional pharmaceutical infrastructure was built for mass-market drugs, Nome provides the coordination layer that rare disease programs require: AI-driven genomic assessment, regulatory navigation, researcher and manufacturer matching, and end-to-end program management — all in oneplatform.Nome serves as a tech-enabled service company sitting between the patient and the clinic. For a patient or family, Nome delivers a free therapy eligibility assessment in 1–2 weeks, followed by an execution-ready action plan. For clinicians and foundations, Nome functions as an intelligent scientific program manager — handling the orchestration complexity that has historically made personalized drug development inaccessible outside of elite academic medical centers.The platform is modality-agnostic, with current focus on antisense oligonucleotides and gene therapies. Nome also operates as a preclinical CRO, offering target design, toxicology studies, and pre-clinical manufacturing services for rare genetic diseases.Founded by Steven Ringel — a rare disease patient, former Sema4, GeneDx, and Tempus operator, and founder of the Kizuna Foundation (foundation to develop retinal gene therapies) — Nome emerged from stealth in October 2025 backed by Twelve Below, Refactor Capital, and Inflect Health. | $2.7M / Seed / Oct 15, 2025 | ||
|
Pilgrim
|
Pioneering a biologically enhanced future for humanity. | $4.3M / Seed / Aug 06, 2025 | |
| Remedy Scientific is a pioneering environmental remediation technology firm. It strives to revolutionize how the world combats environmental contamination. The company focuses on restoring contaminated land using advanced technology, including AI and precise sensors, to return sites to productive use. | $11M / Seed / Apr 09, 2025 | ||
|
Pilgrim
|
Pioneering a biologically enhanced future for humanity. | $3.3M / Pre-Seed / Mar 17, 2025 | |
|
Pilgrim
|
Pioneering a biologically enhanced future for humanity. | Seed / Mar 17, 2025 | |
| See all 120 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Refactor invest in?
Refactor invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 120 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Refactor invest in?
Refactor typically joins rounds of $2.7M–$11M at Seed, $8M–$34M at Series A and $16M–$103M at Series B. These are whole funding-round sizes, not Refactor's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Refactor took part in.
How do I contact Refactor?
Public channels for Refactor include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Refactor?
The team at Refactor includes Zal Bilimoria (Founding Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
